TP53, tumor protein p53, 7157

N. diseases: 2494; N. variants: 527
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C2239176
Disease: Liver carcinoma
Liver carcinoma
1.000 GeneticVariation disease BEFREE Second, we present a meta-analysis, using our results along with those from 48 published studies, that examines the interrelationships among aflatoxin exposure, HBV infection, and p53 mutations in HCCs. 11401911 2001
CUI: C2239176
Disease: Liver carcinoma
Liver carcinoma
1.000 GeneticVariation disease BEFREE Therefore, p53 mutation in the primary lesion is useful as an indicator of the biological behavior of recurrent hepatocellular carcinomas. 12800224 2003
CUI: C2239176
Disease: Liver carcinoma
Liver carcinoma
1.000 AlteredExpression disease BEFREE The relationship between the expression of APE1 and P53 protein and overall survival time of patients with hepatocellular carcinoma has not been found. 26367730 2015
CUI: C2239176
Disease: Liver carcinoma
Liver carcinoma
1.000 Biomarker disease BEFREE We analysed the concentration of p53 in tumor cytosols of 34 primary advanced HCC and with the clinical outcome and survival time. p53 was analysed in the tumor cytosol by luminometric immunoassay (LIA) using monoclonal antibodies detecting wild type and mutant p53 protein. 10470182 1999
CUI: C2239176
Disease: Liver carcinoma
Liver carcinoma
1.000 Biomarker disease BEFREE KIAA0101 tv1 may function as a regulator, promoting cell survival in HCC through regulating the function of p53. 22576474 2012
CUI: C2239176
Disease: Liver carcinoma
Liver carcinoma
1.000 CausalMutation disease CLINVAR
CUI: C2239176
Disease: Liver carcinoma
Liver carcinoma
1.000 AlteredExpression disease BEFREE In this study, we examined mRNA expression by quantitative real-time PCR (qRT-PCR) of HOXA10 as well as histone deacetylase (HDAC) and protein levels by Western blot of HOXA10, HDAC1, Cyclin D1, proliferating cell nuclear antigen (PCNA), Survivin and p53 acetylation in HCC tissues and cell lines. 31440094 2019
CUI: C2239176
Disease: Liver carcinoma
Liver carcinoma
1.000 AlteredExpression disease BEFREE Alterations of the RB tumour suppressor gene in hepatocellular carcinoma and hepatoblastoma cell lines in association with abnormal p53 expression. 8790559 1994
CUI: C2239176
Disease: Liver carcinoma
Liver carcinoma
1.000 AlteredExpression disease BEFREE To clarify whether the level of p53 expression determines the apoptotic response of hepatocellular carcinoma (HCC) cells, we assessed the effect of various levels of expression of p53 gene on a p53-deficient HCC cell line, Hep3B, utilizing a doxycycline (Dox)-regulated inducible p53 expression system. 17191126 2007
CUI: C2239176
Disease: Liver carcinoma
Liver carcinoma
1.000 GeneticVariation disease BEFREE Abnormalities of the RB tumor suppressor gene have been found in 20-25% of HCCs, including 80-86% of HCCs with p53 mutations. 8046425 1994
CUI: C2239176
Disease: Liver carcinoma
Liver carcinoma
1.000 AlteredExpression disease BEFREE We conclude that the loss of p53 expression or the presence of abnormal forms of the protein are frequently associated with HCC cell lines. 2155427 1990
CUI: C2239176
Disease: Liver carcinoma
Liver carcinoma
1.000 Biomarker disease BEFREE Furthermore, pharmacological or RNAi inhibition of the mevalonate pathway restricts the development of murine hepatocellular carcinomas driven by p53 loss. 30580964 2019
CUI: C2239176
Disease: Liver carcinoma
Liver carcinoma
1.000 AlteredExpression disease BEFREE Immunostaining with monoclonal pAb 1801 revealed expression of p53 protein in tumor-cell nuclei in one HCV-associated HCC, and in no case of HBV-associated HCC, while the nuclei of adjacent hepatocytes were negative. 8390407 1993
CUI: C2239176
Disease: Liver carcinoma
Liver carcinoma
1.000 Biomarker disease CTD_mouse Thus, this study supports a model that, in the face of chronic liver damage, attenuated p53 function and telomere-induced chromosomal instability play critical and cooperative roles in the progression of hepatocellular carcinoma. 16651430 2006
CUI: C2239176
Disease: Liver carcinoma
Liver carcinoma
1.000 Biomarker disease BEFREE The p 53 protein produced by this recombinant virus was used to investigate p53 binding proteins in seventeen cell lines, including 10 derived from human hepatocellular carcinoma, four from other human cancers, and three from non-human primate tissues. 7654264 1995
CUI: C2239176
Disease: Liver carcinoma
Liver carcinoma
1.000 Biomarker disease BEFREE By adjustment for oxidative risk factors of HCC, the compound CT and TT genotypes in relative to the CC wild-type were associated with 83% reduced lymphocytic p53 oxidative lesions of HCC patients with RBC folate lower than 688 ng/mL (OR: 0.17, 95%CI: 0.07-0.43). 23996892 2014
CUI: C2239176
Disease: Liver carcinoma
Liver carcinoma
1.000 GeneticVariation disease BEFREE No p53 gene alterations were found in smaller HCC (< 3 cm) or at earlier stages. 8100480 1993
CUI: C2239176
Disease: Liver carcinoma
Liver carcinoma
1.000 Biomarker disease BEFREE Kinases have been targeted for decades with varying results, but the development of therapeutic resistance is a major challenge.<b>Areas covered</b>: The key roles of the RAS/RAF/MEK/ERK, PI3K/PTEN/AKT/mTORC1, TP53 microRNAs (miRs) as therapeutic targets are discussed and we suggests novel approaches for targeting miRs or their downstream targets to combat HCC. 31657972 2019
CUI: C2239176
Disease: Liver carcinoma
Liver carcinoma
1.000 GeneticVariation disease BEFREE We examined tumors from five vinyl chloride-exposed patients, four with ASL and one with hepatocellular carcinoma (HCC), for evidence of MDM2 proto-oncogene amplification or p53 mutation in exons 5-8. 8293534 1994
CUI: C2239176
Disease: Liver carcinoma
Liver carcinoma
1.000 Biomarker disease CTD_human These results suggest the level of p53 expression could determine if the HCC cells would go into cell cycle arrest or apoptosis. 17191126 2007
CUI: C2239176
Disease: Liver carcinoma
Liver carcinoma
1.000 GeneticVariation disease BEFREE To detect the status of loss of heterozygosity (LOH) in HCC and to determine the minimum region of LOH on 17p13.3, we analyzed 22 paired HCC and non-cancerous liver samples with 14 polymorphic markers plus TP53 (p53 gene) as a comparison. 12565177 2003
CUI: C2239176
Disease: Liver carcinoma
Liver carcinoma
1.000 GeneticVariation disease BEFREE In xenograft models, mice bearing TP53-mutated or TP53-deleted human HCCs were hypersensitive to treatment with conformation-changing AURKA inhibitors, thus suggesting a therapeutic strategy for this subgroup of human HCCs. 27213815 2016
CUI: C2239176
Disease: Liver carcinoma
Liver carcinoma
1.000 AlteredExpression disease BEFREE In the 132 matched HCC tissues, high expression levels of CDC20 were detected in 68.18% HCC samples, and overexpression of CDC20 was positively correlated with gender (P=0.013), tumor differentiation (P=0.000), TNM stage (P=0.012), P53 and Ki-67 expression (P=0.023 and P=0.007, respectively). 25069850 2014
CUI: C2239176
Disease: Liver carcinoma
Liver carcinoma
1.000 Biomarker disease BEFREE Circulating antibodies against p53 were found in 25% (20 of 80) of the sera from patients with hepatocellular carcinoma but not in various nonmalignant liver diseases. 7689531 1993
CUI: C2239176
Disease: Liver carcinoma
Liver carcinoma
1.000 GeneticVariation disease BEFREE We analyzed human hepatocellular carcinoma (HCC) by ISH for chromosome 17 and investigated the correlation of its copy number with histologic malignancy, proliferative activity, p53 mutation, and DNA ploidy. 8625234 1996